Sonoma Pharmaceuticals (SNOA) Other Accumulated Expenses (2015 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Other Accumulated Expenses of $533000.0 for Q1 2026, up 9.45% year-over-year from $487000.0 in Q1 2025, and up 9.45% quarter-over-quarter from $487000.0 in Q1 2025.
Sonoma Pharmaceuticals (SNOA) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $533000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 9.45% year-over-year to $533000.0; the TTM figure through Mar 2026 stood at $533000.0 (up 9.45% YoY), while the FY2026 annual figure was $533000.0, up 9.45% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $533000.0, up from $487000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $784000.0 in Q1 2022, with the low at $487000.0 in Q1 2025.
- The 5-year median for Other Accumulated Expenses is $566000.0 (2023), against an average of $612800.0.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses surged 113.62% in 2022, then retreated 29.83% in 2025.
- Sonoma Pharmaceuticals' Other Accumulated Expenses stood at $784000.0 in 2022, then retreated by 27.81% to $566000.0 in 2023, then increased by 22.61% to $694000.0 in 2024, then declined by 29.83% to $487000.0 in 2025, then increased by 9.45% to $533000.0 in 2026.
- Business Quant data shows SNOA's Other Accumulated Expenses at $533000.0 in Q1 2026, $487000.0 in Q1 2025, and $694000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 533,000.00 |
| Mar 31, 2025 | 487,000.00 |
| Mar 31, 2024 | 694,000.00 |
| Mar 31, 2023 | 566,000.00 |
| Mar 31, 2022 | 784,000.00 |
| Mar 31, 2021 | 367,000.00 |
| Mar 31, 2020 | 462,000.00 |
| Sep 30, 2019 | 270,000.00 |
| Jun 30, 2019 | 270,000.00 |
| Mar 31, 2019 | 270,000.00 |
| Dec 31, 2018 | 270,000.00 |
| Mar 31, 2017 | 542,000.00 |
| Mar 31, 2016 | 276,000.00 |
| Mar 31, 2015 | 100,000.00 |